直接作用抗病毒药物治疗丙型肝炎病毒后患者性功能障碍的改善。

Improvement of sexual dysfunction in patients after treatment of hepatitis C virus using directly acting antivirals.

机构信息

Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.

Department of Dermatology and Andrology, Sexual Medicine and STDs, Faculty of Medicine, Helwan University, Cairo, Egypt.

出版信息

Curr Med Res Opin. 2021 Jun;37(6):967-972. doi: 10.1080/03007995.2021.1901677. Epub 2021 Mar 27.

DOI:10.1080/03007995.2021.1901677

PMID:33688780

Abstract

OBJECTIVE

The impact on male and female sexual dysfunction of treating hepatitis C virus (HCV) using direct-acting antiviral agents (DAAs) has not been sufficiently studied. The aim of this study was to assess the impact of HCV clearance with DAAs on sexual dysfunction (SD) in both sexes.

METHODS

In chronic HCV patients who were eligible for DAAs, 100 sexually active men completed the Arabic version of the international index of erectile function questionnaire (IIEF-5), and the same number of sexually active women completed Female Sexual Function Index (FSFI), before, at the end of, and 3 months after, treatment for HCV.

RESULT

The mean of the IIEF-5 scores for male patients was 16.29 ±.07 before treatment, 16.88 ± 3.63 3 months after treatment ( < .01), and was significantly higher, at 19.06 ± 3.31 6 months after treatment cessation ( < .01). In female patients, the mean total FSFI score at baseline was 19.22 ± 2.40 and after 3 months of treatment was 21.61 ± 3.45 ( < .01), with a significant increase (25.09 ± 4.52) after 6 months ( < .01). No difference in the improvement of sexual function was reported either after 3 months or at the end of treatment between males and females ( > .05).

CONCLUSIONS

Significant improvement in SD associated with HCV infection in both sexes was recorded following viral clearance using DAAs treatment.

摘要

目的

直接作用抗病毒药物（DAAs）治疗丙型肝炎病毒（HCV）对男性和女性性功能障碍的影响尚未得到充分研究。本研究旨在评估 HCV 清除对两性性功能障碍（SD）的影响。

方法

在符合 DAA 治疗条件的慢性 HCV 患者中，100 名有性行为的男性患者完成了阿拉伯版国际勃起功能指数问卷（IIEF-5），同样数量有性行为的女性患者完成了女性性功能指数（FSFI），分别在 HCV 治疗前、治疗结束时和治疗后 3 个月进行。

结果

男性患者的 IIEF-5 评分均值在治疗前为 16.29±.07，治疗后 3 个月为 16.88±3.63（<0.01），停药后 6 个月时显著升高，为 19.06±3.31（<0.01）。在女性患者中，基线时的总 FSFI 评分均值为 19.22±2.40，治疗后 3 个月为 21.61±3.45（<0.01），停药后 6 个月时显著增加（25.09±4.52）（<0.01）。在男性和女性中，治疗 3 个月或治疗结束时，性功能改善无差异（>0.05）。